financetom
Business
financetom
/
Business
/
CoreWeave Stock Hits All-Time High: What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CoreWeave Stock Hits All-Time High: What's Going On?
May 26, 2025 11:55 AM

CoreWeave, Inc. ( CRWV ) shares hit a new all-time high on Wednesday. A series of recent developments have drawn investor attention to the AI infrastructure stock.

What To Know: CoreWeave ( CRWV ) has soared this year since making its debut on public markets in March. The company is backed by Nvidia Corp ( NVDA ) , which recently revealed a large stake in the company totaling 24.18 million shares in a regulatory filing. Several analysts have also initiated coverage in recent weeks following the company’s first earnings report as a public company.

CoreWeave ( CRWV ) reported first-quarter results last week showing revenue of $981.6 million, marking a 420% increase from the same period last year. The number was well above analyst forecasts of $859.77 million, according to Benzinga Pro. The company also noted that a strategic deal with OpenAI during the quarter added $11.2 billion in revenue backlog.

Shares surged following the report as the company revealed additional details of its deal with OpenAI, including additional agreements entered into in May to provide the company with access to cloud computing capacity. CoreWeave ( CRWV ) disclosed that OpenAI has committed to pay the company up to $4 billion through April 2029 related to the agreement.

CoreWeave ( CRWV ) on Wednesday announced plans to offer $1.5 billion of senior notes due 2030. Shares surged to new highs despite the offering announcement. The company announced an upsized offering hours later, increasing it from $1.5 billion to $2 billion, but shares continued to trend higher with investor interest at all-time highs.

CoreWeave ( CRWV ) stock is trending on several social platforms Wednesday afternoon with shares now up approximately 155% over the past month.

Citigroup analyst Tyler Radke maintained CoreWeave ( CRWV ) with a Neutral rating and raised the price target from $43 to a Street-high of $94. CoreWeave ( CRWV ) price targets range from $94 to $36, according to Benzinga analyst data.

Related Link: Visa’s Dual Push: Enhancing Fintech Partnerships, Automating Virtual Card Payments

CRWV Price Action: At the time of publication, CoreWeave ( CRWV ) shares were up 18.1% at $106.62, according to data from Benzinga Pro.

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kinder Morgan Q3 Adjusted Earnings, Revenue Increase
Kinder Morgan Q3 Adjusted Earnings, Revenue Increase
Oct 22, 2025
04:29 PM EDT, 10/22/2025 (MT Newswires) -- Kinder Morgan ( KMI ) reported Q3 adjusted earnings late Wednesday of $0.29 per share, up from $0.25 a year earlier. Analysts polled by FactSet expected $0.29. Revenue for the quarter ended Sept. 30 was $4.15 billion, up from $3.70 billion a year earlier. Analysts surveyed by FactSet expected $3.98 billion. Kinder Morgan...
IT staffing firm ASGN Q3 adjusted EPS beats estimates on growth in consulting business
IT staffing firm ASGN Q3 adjusted EPS beats estimates on growth in consulting business
Oct 22, 2025
Overview * ASGN ( ASGN ) Q3 revenue was $1.01 bln, sligthly beating analyst expectations * Adjusted EPS for Q3 was $1.31, surpassing consensus estimates * Company repurchased 0.9 mln shares for $46 mln, reflecting confidence in financial position Outlook * Company expects Q4 2025 revenue between $960 mln and $980 mln * ASGN ( ASGN ) projects Q4 adjusted...
Viking Therapeutics misses Q3 profit estimates
Viking Therapeutics misses Q3 profit estimates
Oct 22, 2025
Overview * Viking Therapeutics ( VKTX ) reports Q3 net loss of $90.8 mln, missing analyst expectations * Company maintains strong cash position of $715 mln to support ongoing clinical trials * VK2735 Phase 2 VENTURE study shows up to 12.2% weight loss, meeting primary endpoints Outlook * Company expects to complete VANQUISH-1 enrollment by end of 2025 * Viking...
Eagle Bancorp's Q3 net loss of $67.5 mln misses analyst expectations
Eagle Bancorp's Q3 net loss of $67.5 mln misses analyst expectations
Oct 22, 2025
Overview * Eagle Bancorp ( EGBN ) Q3 net loss of $67.5 mln, missing analyst expectations * Net interest income rose slightly to $68.2 mln, driven by lower funding costs * Noninterest income fell due to $3.6 mln loan sale loss and $2 mln security sale loss Outlook * Company did not provide specific guidance for future quarters or full...
Copyright 2023-2026 - www.financetom.com All Rights Reserved